PYC Therapeutics Limited (ASX:PYC)
1.485
-0.015 (-1.00%)
At close: Dec 5, 2025
PYC Therapeutics Revenue
In the fiscal year ending June 30, 2025, PYC Therapeutics had annual revenue of 23.49M AUD with 6.51% growth. PYC Therapeutics had revenue of 11.66M in the half year ending June 30, 2025, a decrease of -5.49%.
Revenue
23.49M
Revenue Growth
+6.51%
P/S Ratio
36.87
Revenue / Employee
4.70M
Employees
5
Market Cap
866.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 23.49M | 1.44M | 6.51% |
| Jun 30, 2024 | 22.06M | 6.25M | 39.56% |
| Jun 30, 2023 | 15.81M | -236.57K | -1.47% |
| Jun 30, 2022 | 16.04M | 12.97M | 421.83% |
| Jun 30, 2021 | 3.07M | 678.66K | 28.33% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |